Eli Lilly Just Showed Its Drugs Can Fix More Than Weight

Most drug companies come to a conference to defend what they already sell. Eli Lilly arrived at ObesityWeek 2026 in Washington this weekend and pushed into entirely new disease territory.

Sponsored

NASA Is Paying Elon Musk $843 Million to DESTROY a $150 Billion Space Station

It cost $150 billion and took 16 nations 13 years to build.

It is the most expensive object human beings have ever made.

Now SpaceX has been hired for what one outlet calls “the most expensive demolition job ever commissioned.”

But here is the part almost nobody has caught yet.

Elon is NOT building the replacement.

That job is poised to go to a company less than half a percent the size of SpaceX.

It is the real winner in this deal.

Former Wall Street CEO Dylan Jovine has laid out the whole story, including the tiny firm’s name.

See the full story here

Why This Stock Now

The weekend oral sessions delivered two findings that expand what the LLY franchise actually is. In the TRIUMPH-1 trial, retatrutide reduced knee osteoarthritis pain by up to 4.3 points, or 73.1%, at 80 weeks on the WOMAC pain subscale. TRIUMPH-4 showed WOMAC pain score reductions at 68 weeks, with Lilly reporting decreases of up to 4.5 points, or 75.8%, in its materials. On sleep apnea, Phase 3 data from TRIUMPH-1 showed reductions in obstructive sleep apnea severity, with Lilly reporting a reduction of up to 36.1 apnea-hypopopnea index events per hour, a 60.6% reduction, at 80 weeks. Those are not incremental improvements to an existing label. They are arguments for retatrutide as a drug that treats obesity’s downstream consequences, not merely the weight itself.

The Business

Lilly already commands the obesity market. In the U.S., Lilly said it held a 60.9% share of incretin analog prescriptions in the second quarter, compared with Novo’s 38.8%. That lead is built on tirzepatide’s clinical superiority: Zepbound and Wegovy went head-to-head in a clinical trial, and Zepbound led with a least-squares mean weight loss of 20.2% versus 13.7% at 72 weeks.

The financial engine reflects that dominance. Revenue grew 39% year over year in Q3 2026, and Lilly reported Q3 2026 revenue of $24.4 billion driven primarily by Mounjaro and Zepbound, with those two products totaling about $16.1 billion in the quarter. Lilly raised full-year 2026 revenue guidance to $91 to $92 billion.

Why Wall Street Is Paying Attention

The ObesityWeek dataset gives institutional investors a reason to revisit a stock that had already run hard. Retatrutide cut breathing disruptions during sleep and separately reduced knee osteoarthritis pain scores by up to 73.1% in TRIUMPH-1, positioning it beyond weight-focused labeling, though it remains investigational.

The EloraTZP data added another layer. Phase 2 results showed participants with obesity or overweight and type 2 diabetes lost up to an average of 54.1 pounds, or 23.3%, at 48 weeks; the treatment also lowered A1C by up to an average of 2.9%, with up to 77% of participants achieving normal blood sugar levels and up to 60% no longer meeting BMI criteria for obesity. Those are Phase 2 numbers with all the caveats that implies, but they set a high bar for what Phase 3 would need to replicate.

Sponsored

What Washington Isn’t Telling Retirees Right Now

The election is over. The uncertainty is NOT. Politicians will spend the next two years fighting each other, while YOUR retirement sits exposed to every market swing. Government debt remains enormous, and it didn’t go anywhere on Election Day. If most of your savings are in stocks and bonds, ask yourself one question: Am I diversified ENOUGH? For generations, investors have turned to physical GOLD in uncertain times.

See why GOLD is back in the conversation.

What’s Driving the Opportunity

The retatrutide indications matter beyond the science. Knee osteoarthritis affects hundreds of millions of people globally, and Lilly has said it is studying retatrutide in a broad Phase 3 program that includes obesity and complications such as knee osteoarthritis and obstructive sleep apnea. Each additional approval expands the addressable patient pool without requiring a new commercial infrastructure. The incremental manufacturing and sales cost of treating a Zepbound patient who also has sleep apnea is negligible compared to the incremental revenue from a new indication.

The global market for obesity medicines is widely forecast to keep expanding, and bullish forecasts often cite a market size around $120 billion by the early 2030s. Lilly enters that expansion as the volume leader, with a pipeline that keeps stretching the definition of what a GLP-1 drug can treat.

What Could Go Wrong

The valuation does not leave much room for execution slippage. Lilly’s forward P/E is meaningfully above the drug manufacturers’ industry median. The stock has gained approximately 41% over the past year, and the consensus 12-month price target sits close to where the stock is trading today, implying that most of the near-term good news is already reflected.

Pricing pressure on GLP-1 drugs does not exist in isolation from broader policy shifts. Two government actions within 48 hours — a Medicare Part B pricing model and new pharmaceutical tariffs — landed on the same endocrinology category Lilly dominates.

In Q3 2026, Lilly reported that realized prices declined, and it has pointed to pricing pressure as an ongoing headwind. Any deceleration in Zepbound prescription volumes or a stumble in the retatrutide regulatory path would hit a stock priced for continued outperformance.

Sponsored

He Called Black Monday. He Called the ’95 Tech Boom. He Called the 2009 Bottom. Now He’s Back.

Each time, Dr. Mark Skousen went against the crowd. Each time, the people who listened got a head start. Now “America’s Economist” is out with his boldest call in years.

Watch his briefing free, right here…

Competition is real, even if Novo is currently struggling. Amgen’s MariTide and Viking Therapeutics’ pipeline both target the same patient population, and each Phase 3 readout from a rival chips at the assumption that Lilly stays at 60% market share indefinitely.

Viking’s pipeline is further along than many investors realize. Viking Therapeutics has two fully enrolled Phase 3 trials targeting the same obesity patient population as Lilly.

The Bottom Line

What ObesityWeek 2026 confirmed is that retatrutide is not a next-generation weight loss drug in the narrow sense. It is a cardiometabolic platform. Knee pain cut by three-quarters. Sleep apnea events cut by more than half. A1C normalized in up to 77% of EloraTZP participants in Lilly’s Phase 2 readout. That pipeline depth is what separates Lilly from every other company in this space, including Novo, which is running a turnaround while Lilly runs up the score.

The price already assumes a lot. But the data keeps providing new reasons to justify those assumptions. For investors who want one stock in the most consequential therapeutic category of the decade, LLY today represents the company whose pipeline is widest and whose commercial lead is clearest, even at a premium multiple.

More From Author

One BDC Worth Buying While the Sector Sells Off

Micron Made $133 Billion Last Year. Its P/E Is Below 5.

Live Market Pulse

The charting technology is provided by TradingView. Learn how to use theTradingView Stock Screener.